logo
  

TCR2 Therapeutics Reports Positive Interim Results From Ongoing Phase 1 Portion Of Gavo-cel Trial

TCR2 Therapeutics Inc. (TCRR) announced positive interim results from the ongoing phase 1 portion of the gavo-cel phase 1/2 clinical trial for mesothelin-expressing solid tumors. The company is very encouraged by the progression free survival and overall survival observed among patients with refractory mesothelioma treated so far with gavo-cel in the phase 1 trial. Gavo-cel was generally well tolerated with a manageable adverse event profile in the study.

The primary objectives of the phase 1 portion of the trial are to define the safety profile of gavo-cel in patients whose tumors overexpress mesothelin and to determine the recommended phase 2 dose. The company said the recommended phase 2 dose is being refined after identification of the maximum tolerated dose.

Alfonso Quintás-Cardama, Chief Medical Officer of TCR2, said: "Based on these data and the most recent patient experiencing a very mild safety profile at a cell dose of 3x108/m2, we believe the identification of the recommended phase 2 dose is close at hand."

Shares of TCR2 Therapeutics were up 4% in pre-market trade on Friday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alexander & Hornung, a business unit of Perdue Premium Meat Co., Inc., is recalling around 234,391 pounds of fully cooked pork products citing possible contamination with Listeria monocytogenes, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves ham and pepperoni products that come under various brands and produced on various dates. Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals.
RELATED NEWS
Follow RTT